Cost of Health Care, Diabetes, Pharmaceutical Companies / 28.05.2025

Reasons for the Price Increase of Insulin .jpg The price of insulin keeps on skyrocketing every year. According to the American Diabetes Association, spending on insulin tripled within a decade. By 2022, the cost had hit a staggering $22.3 billion. Between 2017 and 2022, the inflation-adjusted cost of insulin increased by 24%. This is a significant problem since millions of people suffering from Type 1 and Type 2 diabetes can’t go without the drug. Over the years, people have initiated an insulin overpricing lawsuit. In 2023, Eli Lilly settled for $13.5 million and agreed to cap its price at $35 for four years. So why is insulin so expensive in the United States, and what can you do about it?
Cost of Health Care, Diabetes, Pharmacology / 21.10.2024

[caption id="attachment_64143" align="aligncenter" width="500"]diabetes-insulin Source[/caption]

Access to affordable insulin remains a challenge for millions of people living with diabetes around the world, particularly in middle-income countries. To bridge this gap, platforms are emerging that connect patients with high-quality insulin at reduced prices. For individuals struggling to afford their life-saving medication, these services offer a convenient and affordable solution, making a significant impact on global health.

The Global Insulin Crisis

Diabetes affects millions worldwide, and the demand for insulin continues to rise. Major insulin manufacturers, including Novo Nordisk, Eli Lilly, and Sanofi, dominate the global market, producing essential medications for managing blood sugar levels. However, in many parts of the world, including countries like India, Mexico, and the Philippines, insulin prices remain prohibitively high. This leaves a substantial portion of the population without access to the medication they need to live healthy lives. Data shows that insulin prices are often out of reach for people in middle-income countries. The situation is particularly dire in regions like Kenya, Malaysia, and Vietnam, where the cost of insulin may equal a month's salary. With nearly three major companies controlling the insulin market, competition is limited, and prices remain high. As a result, many patients with type 1 and type 2 diabetes face inconsistent access to insulin, which can put their health at significant risk.